Results 31 to 40 of about 14,657 (135)

Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.

PLoS ONE, 2015
Zoledronic acid, a highly potent nitrogen-containing bisphosphonate used for the treatment of pathological bone loss, is excreted unmetabolized via the kidney if not bound to the bone.
Anja Verhulst, Shuting Sun, Charles E McKenna, Patrick C D'Haese   +3 more
doaj   +1 more source

Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early.
Prem Kotian, Archith Boloor, Sushanth Sreenivasan   +2 more
doaj   +1 more source

The Effect of Zoledronic Acid on BSP Expression and Methylation during Osteoblastic Differentiation of Mesenchymal Stem Cells [PDF]

پیاورد سلامت, 2011
Background and Aim: Bone sialoprotein (BSP) is a specific marker of osteoblastic differentiation. In this research, the effect of Zoledronic Acid on BSP expression and methylation status during osteoblastic differentiation of mesenchymal stem cells (MSCs)
M Mahmodi Niya Meymand, S Kaviyany, M Soleymani, Y Mortazavi, M Nowrozi Niya, M Farsh Dusty Hagh   +5 more
doaj   +2 more sources

Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles

International Journal of Nanomedicine, 2013
Li Chen,1 Yunfei Ding,2 Yongzhong Wang,3 Xingrong Liu,2 RJ Babu,1 WR Ravis,1 Weili Yan21Department of Pharmaceutical Sciences, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 2Department of Pharmaceutical Sciences, College of Life ...
Yan W, Ravis WR, Babu RJ, Liu X, Wang Y, Ding Y, Chen L   +6 more
doaj  

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Journal of Bone Oncology, 2019
Background: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. Objectives: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with ...
Shenglong Li, Peng Chen, Qiankun Yang
doaj   +1 more source

Zoledronic-acid [PDF]

Reactions Weekly, 2020
  +5 more sources

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.

PLoS ONE, 2015
While targeted therapy brought a new era in the treatment of BRAF mutant melanoma, therapeutic options for non-BRAF mutant cases are still limited. In order to explore the antitumor activity of prenylation inhibition we investigated the response to ...
Tamás Garay, István Kenessey, Eszter Molnár, Éva Juhász, Andrea Réti, Viktória László, Anita Rózsás, Judit Dobos, Balázs Döme, Walter Berger, Walter Klepetko, József Tóvári, József Tímár, Balázs Hegedűs   +13 more
doaj   +1 more source

Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt pathways

Journal of Experimental & Clinical Cancer Research, 2019
Background Zoledronic acid is the most potent osteoclast inhibitor and is widely used for advanced cancer patients with bone metastasis, but its role on cancer stem cells (CSCs) remains unclear.
Li Wang, Yanyang Liu, Yueling Zhou, Jiantao Wang, Li Tu, Zhen Sun, Xiujie Wang, Feng Luo   +7 more
doaj   +1 more source

TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION

Остеопороз и остеопатии, 2013
Infusions of aminobisphosphonates are now established therapies ofpostmenopausal osteoporosis. Their use is associated with fever and musculoskeletal pain in some subjects, referred to as the acute phase response (APR).
O V Yakushevskaya, S V Yureneva
doaj   +1 more source

Efficacy evaluation of denosumab in the treatment of patients with postmenopausal osteoporosis at high risk of fracture

Zhongguo Linchuang Yixue
ObjectiveTo explore the difference of efficacy and safety between denosumab and zoledronic acid in the treatment of patients with postmenopausal osteoporosis (PMOP), and to optimize the medication regimen for PMOP patients.
Jing ZHOU, Xingyun HOU, Tingting LIU, Jiaoyang ZHENG   +3 more
doaj   +1 more source